Expression of cysteine rich 61 and vascular endothelial growth factor in patients with multiple myeloma and their relationship with staging and therapeutic response
10.3760/cma.j.issn.1009-9921.2013.08.011
- VernacularTitle:富半胱氨酸61、血管内皮生长因子表达与多发性骨髓瘤分期及疗效的关系
- Author:
Zhimin WANG
;
Zunchang LI
;
Xuexia PAN
;
Qiangyuan TIAN
;
Yanxin HAN
;
Yaqin CONG
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Cysteine rich 61;
Vascular endothelial growth factor;
Polymerase chain reaction
- From:
Journal of Leukemia & Lymphoma
2013;22(8):487-490
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of cystein rich 61 (Cyr61) and vascular endothelial growth factor (VEGF) in different stages of multiple myeloma (MM) patients,evaluate their relationship with angiogenesis and prognosis,and to determine the relationship between Cyr61 and VEGF.Methods Expression of Cyr61 and VEGF in BMMNC from 31 patients with different stages of MM and 10 cases of control were detected by RT-PCR.Results Expression of Cyr61 and VEGF in patients with MM (0.3652±1.5423,0.4815±1.3423) were significantly elevated in comparison to control (0.1862±0.7542,0.2012±1.2331) (P ＜ 0.05,P ＜ 0.01).Expression of Cyr61 and VEGF in stage Ⅲ (0.4632±0.1634,0.5356± 0.2342) was significantly higher than those in stage Ⅰ and stage Ⅱ (t =2.423,2.524,P ＜ 0.05),but there was no difference between stage Ⅰ and stage Ⅱ (0.2513±0.1365,0.3064±0.2124; 0.3084±0.2254,0.3653±0.1265) (t =1.782,1.824,P ＞ 0.05).The levels of Cyr61 and VEGF were significantly decreased after chemotherapy compared to before chemotherapy (P ＜ 0.01).Expression of Cyr61 and VEGF were positively correlated (r =0.8941,P ＜ 0.01).Conclusion Cyr61 and VEGF may play roles in the angiogenesis and pathophysiology of MM.It can be used to guide treatment and estimate prognosis by monitoring Cyr61 and VEGF.
